Crohn's Disease

SAN DIEGO — Black patients with inflammatory bowel disease were more likely to use older therapies and face continued barriers to effective care, according to survey results presented at Digestive Disease Week 2022.

Sometimes, the best way to care for a patient is to know one’s own limitations.

SAN DIEGO — Subcutaneous infliximab maintained remission among patients with inflammatory bowel disease who switched from IV dosing, according to research presented at Digestive Disease Week.

SAN DIEGO — Dog ownership and close interactions with these pets in early childhood could help prevent later development of Crohn’s disease, according to data presented at Digestive Disease Week 2022.

SAN DIEGO — A novel blood protein panel correlated with tumor necrosis factor antagonist treatment failure had modest predictive capacity among patients newly diagnosed with Crohn’s disease, according to research.

SAN DIEGO — Corticosteroid use should be minimized in patients with inflammatory bowel disease to reduce the risk for invasive fungal infections, according to research presented at Digestive Disease Week 2022.

SAN DIEGO — Baseline magnetic resonance index of activity score independently predicted the longer-term need for surgery, rescue corticosteroids or hospitalizations among patients with Crohn’s disease.

The first reported incident of emphysematous cystitis in a patient with severe Crohn’s disease, without UTI or fistulizing disease, may signal “poor prognosis” for these patients, according to a case report published in BMC Gastroenterology.

The use of antibiotics, particularly those targeting gastrointestinal pathogens, was associated with an increased risk for older-onset inflammatory bowel disease, according to a researcher at the Digestive Disease Week 2022 media briefing.

Anti-tumor necrosis factor therapy had reduced efficacy and safety for bio-naive patients with older-onset inflammatory bowel disease compared with younger patients, according to a study published in Scientific Reports.